Literature DB >> 15713436

Overexpression of RGC-32 in colon cancer and other tumors.

Matthew Fosbrink1, Cornelia Cudrici, Florin Niculescu, Tudor C Badea, Stefan David, Abulkalam Shamsuddin, Moon L Shin, Horea Rus.   

Abstract

Tumors often exhibit deregulation of the cell cycle and overexpression of cyclins and cyclin-dependent kinases (CDKs). Response gene to complement (RGC)-32 is a substrate and regulator of CDC2 and its overexpression induces cell cycle activation. We investigated RGC-32 mRNA and protein expression in tumors with special emphasis in colon carcinoma. By using an expression array technique we found that 19% of tumor tissues showed increased RGC-32 mRNA expression over the levels of corresponding normal tissues. On the other hand, an increased RGC-32 protein was found in 70% of colon adenocarcinoma samples tested. In colon carcinomas, two major patterns of RGC-32 immunoreactivity were seen: staining of malignant epithelial cells only in some tumors and RGC-32 reactivity of both malignant epithelia as well as cells in the interstitium in others. Colonic epithelium obtained from normal individuals was consistently negative for RGC-32 protein. Overexpression of RGC-32 protein was found in other tumors including prostate, bladder, breast, lung, and other digestive tract tumors. RGC-32 expression was present in the same malignant epithelial cells that also expressed the proliferation marker Ki-67. Our data suggest that RGC-32 overexpression might be part of the deregulation of the cell cycle that is required for the growth of tumor cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15713436     DOI: 10.1016/j.yexmp.2004.11.001

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  34 in total

Review 1.  The Role of Stem Cell DNA Methylation in Colorectal Carcinogenesis.

Authors:  Lele Song; Yuemin Li
Journal:  Stem Cell Rev Rep       Date:  2016-10       Impact factor: 5.739

2.  Hypoxia-inducible factor 1α participates in hypoxia-induced epithelial-mesenchymal transition via response gene to complement 32.

Authors:  Liang Zhu; Qiu Zhao
Journal:  Exp Ther Med       Date:  2017-06-23       Impact factor: 2.447

3.  RGC-32 Deficiency Protects against Hepatic Steatosis by Reducing Lipogenesis.

Authors:  Xiao-Bing Cui; Jun-Na Luan; Shi-You Chen
Journal:  J Biol Chem       Date:  2015-07-01       Impact factor: 5.157

4.  RGC32 deficiency protects against high-fat diet-induced obesity and insulin resistance in mice.

Authors:  Xiao-Bing Cui; Jun-Na Luan; Jianping Ye; Shi-You Chen
Journal:  J Endocrinol       Date:  2014-11-10       Impact factor: 4.286

5.  Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors.

Authors:  Christiane M Robbins; Waibov A Tembe; Angela Baker; Shripad Sinari; Tracy Y Moses; Stephen Beckstrom-Sternberg; James Beckstrom-Sternberg; Michael Barrett; James Long; Arul Chinnaiyan; James Lowey; Edward Suh; John V Pearson; David W Craig; David B Agus; Kenneth J Pienta; John D Carpten
Journal:  Genome Res       Date:  2010-12-08       Impact factor: 9.043

Review 6.  Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer.

Authors:  Sonia I Vlaicu; Cosmin A Tegla; Cornelia D Cudrici; Jacob Danoff; Hassan Madani; Adam Sugarman; Florin Niculescu; Petru A Mircea; Violeta Rus; Horea Rus
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

7.  Responses of cultured human keratocytes and myofibroblasts to ethyl pyruvate: a microarray analysis of gene expression.

Authors:  Stephen A K Harvey; Emily Guerriero; Nahthai Charukamnoetkanok; Jordan Piluek; Joel S Schuman; Nirmala Sundarraj
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-01-06       Impact factor: 4.799

8.  Overexpression of response gene to complement 32 (RGC32) promotes cell invasion and induces epithelial-mesenchymal transition in lung cancer cells via the NF-κB signaling pathway.

Authors:  Qinying Sun; Xiaopeng Yao; Yunye Ning; Wei Zhang; Guowu Zhou; Yuchao Dong
Journal:  Tumour Biol       Date:  2013-05-29

9.  Epigenetic modifications induced by RGC-32 in colon cancer.

Authors:  Sonia I Vlaicu; Cosmin A Tegla; Cornelia D Cudrici; Matthew Fosbrink; Vingh Nguyen; Philippe Azimzadeh; Violeta Rus; Hegang Chen; Petru A Mircea; Abulkalam Shamsuddin; Horea Rus
Journal:  Exp Mol Pathol       Date:  2009-10-31       Impact factor: 3.362

10.  Response gene to complement 32, a novel hypoxia-regulated angiogenic inhibitor.

Authors:  Xiaojin An; Yi Jin; Hongnian Guo; Shi-Yin Foo; Brittany L Cully; Jiaping Wu; Huiyan Zeng; Anthony Rosenzweig; Jian Li
Journal:  Circulation       Date:  2009-08-03       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.